Voices

Al-Ola A Abdallah: A Summary Table Between JNJ-5322 Trispecific Study vs Redirect Trial

Al-Ola A Abdallah/LinkedIn

Aug 9, 2025, 03:34

Al-Ola A Abdallah: A Summary Table Between JNJ-5322 Trispecific Study vs Redirect Trial

Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on X:

“A Quick Look at JNJ-5322 Trispecific Antibody Study (Baseline Data): Both sides Good and Bad!

Phase 1 trial investigates JNJ-5322, a trispecific antibody targeting BCMA, GPRC5D, and CD3 for relapsed/refractory

‘Double lock-down’ strategy binds two myeloma antigens to boost T-cell–mediated killing.

Al-Ola A Abdallah

Baseline Characteristics (N=147)

Triple-class exposed: 100%
Penta-drug exposed: 83%
Prior BCMA: 22%
Prior GPRC5D: 14%
Extramedullary disease: 27%
Median prior LOTs: 4
Median age: 64

Safety: Treatment-Emergent AEs

Hematologic (Grade 3/4, RP2D):

Neutropenia: 31%
Anemia: 14%
Lymphopenia: 28%

Infections:

Any grade: 81%
Grade 3/4: 33%
Hypogammaglobulinemia: 50%
2 infection-related deaths

(Adenoviral encephalitis, Pneumonia)

CRS: 22% (all Grade 1–2)
No Grade ≥3 CRS or ICANS reported.

Most Common Infections

URTI: 39%
Pneumonia: 17% (Grade 3/4: 11%)
COVID-19: 14%
IVIG support: 47%

Other: Nasopharyngitis (11%), UTIs (14%)

Taste & Skin-Related Side Effects: similar to Talquetamab

Taste-related:
– RP2D: 68%
– All: 58%
– Mostly low grade

Skin (non-rash):
– RP2D: 64%
– All: 51%

Nail-related:
– RP2D: 33%
– All: 30%

Closer look at efficacy

ORR;

In BCMA/GPRC5D-naive patients:
– ORR: 100%
– VGPR or better: 93%
– CR/sCR: 75%

In BCMA/GPRC5D-exposed patients:
– ORR: 55%
– CR/sCR: 15%

Median time to response: 1.4 mo
Median follow-up: 12.2 mo

Al-Ola A Abdallah

PFS (Progression-Free Survival)

In BCMA/GPRC5D-naive patients:
– 12-month PFS:
95.0% at RP2D
74.1% across all doses

Al-Ola A Abdallah

A Summary table (not a direct Comparison) between JNJ-5322 trispecific (GPRC5D/BCMA/CD3) Study vs Redirect trial (Teclistamab/Talquetamab).”

Al-Ola A Abdallah